#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4572	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2674	503.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1728	1728	C	701	C,T	623,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7208	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4115	523.7	0	.	n	.	0	T695C	SNP	695	695	T	1420	1420	C	552	C,T,A	493,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7208	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4115	523.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	2062	2062	A	610	A,G,C	546,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7208	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4115	523.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2696	2696	C	690	C	629	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7208	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4115	523.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3322	3322	T	601	T	538	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7208	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4115	523.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2770	2770	A	697	A	629	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	718	folP	852	852	100.0	folP.l15.c4.ctg.1	2033	105.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1359	1361	AGC	155;155;154	A,C;G;C	134,1;139;133	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1548	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4350	106.8	1	SNP	p	S91F	0	.	.	271	273	TCC	1205	1207	TCC	138;138;136	T;C;C	124;125;124	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1548	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4350	106.8	1	SNP	p	D95G	0	.	.	283	285	GAC	1217	1219	GAC	138;137;137	G;A;C	127;122;126	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1548	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4350	106.8	1	SNP	p	D95N	0	.	.	283	285	GAC	1217	1219	GAC	138;137;137	G;A;C	127;122;126	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	696	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1652	124.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	414	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1515	81.6	0	.	n	.	0	C187G	SNP	187	187	C	785	785	G	169	G	146	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1492	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3328	133.9	1	SNP	p	D86N	0	.	.	256	258	GAC	707	709	GAC	160;160;159	G;A,C,G;C,A	136;132,2,1;139,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1492	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3328	133.9	1	SNP	p	S87R	0	.	.	259	261	AGT	710	712	AGT	159;162;161	A,C,G;G;T	132,2,1;143;139	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1492	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3328	133.9	1	SNP	p	S87W	0	.	.	259	261	AGT	710	712	AGT	159;162;161	A,C,G;G;T	132,2,1;143;139	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1492	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3328	133.9	1	SNP	p	S87I	0	.	.	259	261	AGT	710	712	AGT	159;162;161	A,C,G;G;T	132,2,1;143;139	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1492	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3328	133.9	1	SNP	p	S88P	0	.	.	262	264	TCC	713	715	TCC	163;164;165	T;C;C	144;144;146	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1282	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3039	126.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1765	1767	GGC	165;165;165	G;G;C,A	150;148;150,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1110	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3050	109.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1592	1594	GCA	148;149;149	G;C,T;A,C	129;128,1;132,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1110	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3050	109.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1595	1597	ATC	153;152;152	A;T,A;C,G	140;137,1;138,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1110	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3050	109.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1607	1609	GTG	157;156;156	G,A;T,C,G;G,C,T	139,1;133,1,1;132,1,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1110	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3050	109.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1607	1609	GTG	157;156;156	G,A;T,C,G;G,C,T	139,1;133,1,1;132,1,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1110	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3050	109.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2111	2113	ACC	130;129;130	A;C;C,G	117;116;114,2	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1110	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3050	109.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2165	2167	GCG	120;119;118	G;C,G,T,A;G	113;96,2,1,1;105	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1110	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3050	109.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2165	2167	GCG	120;119;118	G;C,G,T,A;G	113;96,2,1,1;105	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1110	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3050	109.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2288	2290	GGC	128;129;129	G;G,A;C	111;108,1;110	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1110	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3050	109.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2297	2299	GGC	132;130;131	G;G;C,G	110;111;110,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1110	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3050	109.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2315	2317	CCG	136;137;138	C;C;G,C	113;117;111,2	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1406	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3590	117.2	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1953	1955	CTG	111;109;110	C;T,C;G	97;93,1;96	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	776	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2371	97.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	715	715	C	124	C	117	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	102	porB1a	984	177	90.61	porB1a.l15.c4.ctg.2	309	3.4	0	.	p	.	0	H217N	NONSYN	649	651	CAT	157	159	AAT	3;3;3	A;A;T	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	102	porB1a	984	177	90.61	porB1a.l15.c4.ctg.2	309	3.4	0	.	p	.	0	D218N	NONSYN	652	654	GAT	160	162	AAT	3;3;3	A;A;T	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	102	porB1a	984	177	90.61	porB1a.l15.c4.ctg.2	309	3.4	0	.	p	.	0	A222V	NONSYN	664	666	GCT	172	174	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	102	porB1a	984	177	90.61	porB1a.l15.c4.ctg.2	309	3.4	0	.	p	.	0	V226A	NONSYN	676	678	GTA	184	186	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	102	porB1a	984	177	90.61	porB1a.l15.c4.ctg.2	309	3.4	0	.	p	.	0	.	MULTIPLE	700	702	ACT	207	209	GTA	3;3;3	G;T;A	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	102	porB1a	984	177	90.61	porB1a.l15.c4.ctg.2	309	3.4	0	.	p	.	0	N237fs	FSHIFT	709	709	A	216	216	A	3	A	3	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	G38E	NONSYN	112	114	GGA	590	592	GAA	189;190;190	G;A,G;A	167;170,1;170	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	S46G	NONSYN	136	138	AGC	614	616	GGC	192;192;192	G;G;C,T	168;172;168,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	620	622	GGA	194;194;195	G;G;A	171;173;175	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	T87A	NONSYN	259	261	ACT	737	739	GCT	185;185;185	G,A;C;T,G	166,1;164;161,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	T89S	NONSYN	265	267	ACC	743	745	AGC	184;185;186	A,G;G,C;C	161,1;164,1;167	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	.	MULTIPLE	358	359	AA	835	836	CG	170;169	C;G	154;150	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	.	MULTIPLE	361	362	GA	838	840	CAG	170;170;170	C,T;A,G;G,C	153,1;152,1;154,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	N122K	NONSYN	364	366	AAC	842	844	AAA	167;167;167	A;A;A	150;145;143	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	K143E	NONSYN	427	429	AAA	905	907	GAA	159;159;159	G,A;A,G;A,C	147,1;144,1;144,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	V151A	NONSYN	451	453	GTA	929	931	GCA	157;159;159	G;C,A;A	145;146,1;147	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	1037	1039	CGA	152;150;151	C;G,A;A	141;137,1;144	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1121	1123	ACT	152;152;152	A,T;C,A;T	139,1;137,1;136	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	1124	1126	CAT	152;153;153	C,T;A;T	137,1;138;140	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1130	1132	ATG	153;153;153	A,G;T;G,C	141,1;141;139,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	.	MULTIPLE	766	767	AC	1244	1246	GCA	144;144;143	G;C;A	135;131;132	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	W257R	NONSYN	769	771	TGG	1248	1250	CGG	141;142;142	C;G;G	135;135;128	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	0	.	p	.	0	S258fs	FSHIFT	772	772	A	1251	1251	A	143	A	127	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	1	SNP	p	G120K	1	.	.	358	360	AAG	835	837	CGG	170;169;170	C;G;G	154;150;150	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	1	SNP	p	A121D	1	.	.	361	363	GAC	838	841	CGC	170;170;169	C,T;G,C;C	153,1;154,1;154	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	882	porB1b	1047	1047	96.57	porB1b.l15.c17.ctg.1	1838	141.2	1	SNP	p	D121N	0	.	.	361	363	GAC	838	841	CGC	170;170;169	C,T;G,C;C	153,1;154,1;154	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2696	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5298	152.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2258	2260	AAT	155;155;155	A;A,C;T	138;137,1;132	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	452	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1566	86.5	1	SNP	p	V57M	1	.	.	169	171	ATG	746	748	ATG	165;166;169	A;T;G	155;155;159	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
